N-苯基吗啉-4-磺酰胺 | 90470-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苯基吗啉-4-磺酰胺
• 英文名称: N-phenylmorpholine-4-sulfonamide
• CAS: 90470-88-5
• 化学式: C₁₀H₁₄N₂O₃S
• 分子量: 242.299
• InChiKey: AHURAECPPFGEHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  392.7±52.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  67
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  溴苯 、 4-吗啉磺酰胺 在 tris(dibenzylideneacetone)dipalladium (0) caesium carbonate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 以30%的产率得到N-苯基吗啉-4-磺酰胺
  参考文献：
  名称：

  Novel N-Aryl and N-Heteroaryl Sulfamide Synthesis via Palladium Cross Coupling

  摘要：

  A novel and efficient synthesis of N-aryl and N-heteroaryl sulfamides via an intermolecular palladium-catalyzed coupling process has been developed. The reactions proceeded with good to excellent yields and were tolerant of a wide range of functional groups.

  DOI：

  10.1021/ol049091l

文献信息

• [EN] FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS THIAZOLE ET THIOPHÈNE FUSIONNÉS COMME INHIBITEURS DE KINASE
  申请人：UCB PHARMA SA

  公开号：WO2009071895A1

  公开（公告）日：2009-06-11

  A series of fused bicyclic thiazole and thiophene derivatives which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, and in the 4-position by hydroxy, oxo or an amine moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. (I)

  一系列在2位被一个可选择取代的吗啡啉-4-基团取代，并在4位被羟基、酮基或胺基团取代的融合双环噻唑和噻吩衍生物，作为选择性PI3激酶酶抑制剂，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病方面。（I）
• [EN] TRICYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS TRICYCLIQUES DE KINASE
  申请人：UCB PHARMA SA

  公开号：WO2009071890A1

  公开（公告）日：2009-06-11

  A series of fused tricyclic thiazole and thiophene derivatives which are substituted in the 2-position of the thiazole or thiophene ring by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列融合的三环噻唑和噻吩衍生物，其在噻唑或噻吩环的2位被一个可选择取代的吗啡啉-4-基团取代，是选择性PI3激酶酶抑制剂，在医学上具有益处，例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛性或眼科疾病方面。
• [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123738A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

  该发明涉及公式（I）中R1、R2、R3、R4、R5和p的化合物，其中这些参数在说明和权利要求中有定义，以及其药学上可接受的盐本身和作为药用活性物质，其制备方法，基于与该发明相符合的化合物的药物，以及它们的生产，以及在控制或预防上述疾病方面使用与该发明相符合的化合物，以及分别用于生产相应的药物。
• [EN] HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION
  申请人：C & C RES LAB

  公开号：WO2014196793A1

  公开（公告）日：2014-12-11

  A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

  由式(I)表示的杂环衍生物，或其药用可接受的盐或立体异构体，对STAT3蛋白激活具有抑制作用，并可用于预防或治疗与STAT3蛋白激活相关的疾病。
• BRIDGED PHENANTHRIDINES
  申请人：Ralbovsky Janet L.

  公开号：US20080214537A1

  公开（公告）日：2008-09-04

  Bridged phenanthridine compounds having the structure of formula I or of formula II are provided: These compounds are useful as cannabinoid receptor ligands and can be prepared as pharmaceutical compositions for the prophylaxis or treatment of a variety of diseases, disorders and conditions including inflammatory pain, visceral pain, postoperative pain, cancer pain, neuropathic pain, musculoskeletal pain, dysmenorrhea, menstrual pain, migraine, headache as well as inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, psoriasis, eczema, multiple sclerosis, diabetes and thyroiditis. The compounds can also be used in the treatment of skin disorders, lung disorders, ophthalmic disorders, gastrointestinal disorders, cardiovascular disorders, as well as neurodegenerative, neuroinflammatory and certain psychiatric disorders.

  提供具有结构式I或结构式II的桥联菲啰啉化合物：这些化合物可用作大麻素受体配体，并可制备为用于预防或治疗各种疾病、紊乱和症状的药物组合物，包括炎症性疼痛、内脏疼痛、术后疼痛、癌症疼痛、神经病性疼痛、肌肉骨骼疼痛、痛经、月经疼痛、偏头痛、头痛以及风湿性关节炎、系统性红斑狼疮、克罗恩病、牛皮癣、湿疹、多发性硬化症、糖尿病和甲状腺炎等炎症性疾病。这些化合物还可用于治疗皮肤疾病、肺部疾病、眼科疾病、胃肠疾病、心血管疾病，以及神经退行性疾病、神经炎症性疾病和某些精神疾病。